Although no drugs targeting 5-HT4R are approved to treat MDD, the study of the 5-HT4R system is of particular interest as preclinical studies point to the 5-HT4R as being a promising novel target for fast-acting antidepressant treatment [16, 17]. Here, HTR4 is linked to major depressive disorder.